End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
695 MXN | +1.39% | +0.65% | -19.89% |
05-30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
05-30 | Bristol Myers: FDA approval for Breyanzi | CF |
Sales 2024 * | 46.09B 783B 3,617B | Sales 2025 * | 46.06B 783B 3,615B | Capitalization | 83.29B 1,415B 6,537B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -91.99B -425B | Net income 2025 * | 10.22B 174B 802B | EV / Sales 2024 * | 2.65 x |
Net Debt 2024 * | 39.03B 663B 3,064B | Net Debt 2025 * | 31.68B 538B 2,486B | EV / Sales 2025 * | 2.5 x |
P/E ratio 2024 * |
-15.6
x | P/E ratio 2025 * |
7.77
x | Employees | 34,100 |
Yield 2024 * |
5.86% | Yield 2025 * |
6.15% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +1.39% | ||
1 week | +0.65% | ||
1 month | -8.40% | ||
3 months | -19.19% | ||
6 months | -18.90% | ||
Current year | -19.89% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 31/01/15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19/11/19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19/11/19 |
Peter Arduini
BRD | Director/Board Member | 59 | 31/03/16 |
Derica Rice
BRD | Director/Board Member | 59 | 31/08/20 |
Date | Price | Change | Volume |
---|---|---|---|
31/05/24 | 695 | +1.39% | 3,960 |
30/05/24 | 685.5 | -0.22% | 1,829 |
29/05/24 | 687 | +0.61% | 892 |
28/05/24 | 682.8 | -1.12% | 825 |
24/05/24 | 690.5 | -0.60% | 168 |
End-of-day quote Mexican S.E., May 30, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- BMY Stock
- BMY * Stock